Akso Health Group (AHG) SEC Filings & Earnings Calls
EquiReason read 4 Akso Health Group SEC filings in the last 12 months. Latest: 20-F on 2026-07-23 — Annual report for a small China-based healthcare company; cash nearly depleted; significant regulatory and delisting risks..
Source: SEC EDGAR filings · read by EquiReason
- Market cap
- 1.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- —
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
23 Jul 202620-FAnnual report for a small China-based healthcare company; cash nearly depleted; significant regulatory and delisting risks.open
Figures in the filing · each found in the filing text
| Cash in bank · FY2026 | $200000.00 | -100% y/y |
| Loan due to related parties · FY2026 | $2M | 0% y/y |
Risks flagged
China regulatory crackdown risk
“The PRC government has significant oversight and discretion over the conduct of our operations and may intervene or influence our operations as the government deems appropriate to further regulatory, political and social goals.” · word for word
Delisting risk under HFCA Act
“Our ADSs may be prohibited from trading on a national exchange or over-the-counter under the Holding Foreign Companies Accountable Act (the 'HFCA Act') if the Public Company Accounting Oversight Board (United States) (the 'PCAOB') is unable to inspect our auditors for three consecutive years beginning in 2021.” · word for word
Cash depletion risk
“As of March 31, 2026 and March 31, 2025, we had approximately USD 0.2 million and USD 176.2 million of cash in bank, respectively.” · word for word
10 Feb 20266-KFurnishing of unaudited interim financial statements for six months ended September 30, 2025. Net loss attributable to shareholders $1.28M vs $0.59M in prior period. Revenue flat at $7.0M.open
Figures in the filing · each found in the filing text
| Revenue · H1-2025 | $7M | +1% y/y |
| Net loss attributable to shareholders · H1-2025 | $-1M | |
| Cash and cash equivalents · 2025-09-30 | $11M |
Risks flagged
Significant cash burn: cash dropped from $176M to $11M, with $176M in advances for capital expenditures.
“Cash and cash equivalents $11,128,627 as of September 30, 2025 vs $176,229,874 as of March 31, 2025; Advances for capital expenditures $175,664,545”
Akso Health Group — questions
- What did Akso Health Group file recently?
- 4 SEC filings in the last 12 months. Latest: 20-F on 2026-07-23 — Annual report for a small China-based healthcare company; cash nearly depleted; significant regulatory and delisting risks.
Every figure on this page comes from Akso Health Group's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.